$0.94+22.5%Nov 13 close
The latest quarter (ended September 30, 2026) is from Cerenome’s earnings press release of November 13, 2026. It will be replaced by the official quarterly report (10-Q) once Cerenome files it.
Just reported
From Cerenome, Inc.'s results release of November 13, 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Actual
$722K
-48% y/y
+76% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $722K | $1.4M | -48.32% |
| Profit | -$8.7M | -$4.4M | -95.73% |
| Free Cash Flow | -$7.7M | -$2.6M | -200.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Cerenome, Inc. reported on November 13, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Recognition of our first quarter of CNSide® diagnostic revenue and commercial payments beginning in October is a tremendous landmark,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
(LM) Leptomeningeal metastases (LM) are a rare but severe complication of advanced cancer, affecting the fluid-lined structures of the central nervous system. LM occurs in approximately 5% of patients with metastatic cancer, with breast cancer, lung cancer, and melanoma being the most common sources. Median survival is typically 2-6 months, and effective treatment options are limited, highlighting the urgent need for novel therapies.
The company’s own description, as it appears at the foot of the release.
The quote, the company description and the latest quarter come from Cerenome’s earnings press release (an Item 2.02 8-K) filed November 13, 2026. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Read the release on EDGAR Share prices are split- and dividend-adjusted.